Thursday, April 23, 2015

Seeking Alpha: Alnylam Strengthens Its Clinical Case Once Again

I can understand why many investors may be skeptical of Alnylam Pharmaceuticals (NASDAQ:ALNY). With a $10 billion market cap (as of last night's close), I believe this is the most highly-valued biotech without an actual approved drug. That creates considerable downside risk when (and I do believe it's "when", not "if") a clinical disappointment occurs.

The thing is, though, that Alnylam continues to make its case stronger and stronger. Not only has the company been very active in filling out a robust clinical pipeline, but the incremental data from those drugs has also been quite strong. Alnylam's latest announcement, positive 12-month data from an open-label extension study of patisiran, only serves to highlight that this biotech may in fact be developing a collection of medicines that deliver clear and significant benefits in a variety of undertreated conditions.

Read the full article here:
Alnylam Strengthens Its Clinical Case Once Again

No comments: